
    
      Patients will be screened within 6 weeks prior to Week 1. A total of 3 cohorts, consisting of
      3 to 6 patients each, are planned to receive five to eight intradermal (ID) injections
      totaling 1 mL up to 1.6mL of BPX-101 at 3 doses levels for an initial 6 doses.
    
  